Brent A. Blumenstein

16.6k total citations · 9 hit papers
123 papers, 12.0k citations indexed

About

Brent A. Blumenstein is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Brent A. Blumenstein has authored 123 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 35 papers in Surgery and 30 papers in Oncology. Recurrent topics in Brent A. Blumenstein's work include Prostate Cancer Treatment and Research (34 papers), Bladder and Urothelial Cancer Treatments (22 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Brent A. Blumenstein is often cited by papers focused on Prostate Cancer Treatment and Research (34 papers), Bladder and Urothelial Cancer Treatments (22 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Brent A. Blumenstein collaborates with scholars based in United States, Canada and France. Brent A. Blumenstein's co-authors include E. David Crawford, Mario A. Eisenberger, David G. McLeod, E. David Crawford, Michael F. Sarosdy, Joseph T. Spaulding, F. Andrew Dorr, Bruce A. Lowe, Ralph C. Benson and Phyllis J. Goodman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Brent A. Blumenstein

121 papers receiving 11.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

2001 1.2k citations Robert C. Flanigan, Sydney E. Salmon et al. New England Journal of Medicine profile →
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

1989 1.2k citations E. David Crawford, Mario A. Eisenberger et al. New England Journal of Medicine profile →
MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

2000 891 citations Donald L. Lamm, Brent A. Blumenstein et al. profile →
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

2003 737 citations Brent A. Blumenstein et al. Journal of Clinical Oncology profile →
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 727 citations Brent A. Blumenstein et al. Journal of Clinical Oncology profile →
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

1998 685 citations Mario A. Eisenberger, Brent A. Blumenstein et al. New England Journal of Medicine profile →
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer

2013 575 citations Timothy R. Church, Michael Wandell et al. Gut profile →
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

2003 541 citations Brent A. Blumenstein et al. Journal of Clinical Oncology profile →
A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder

1991 469 citations Donald L. Lamm, Brent A. Blumenstein et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Brent A. Blumenstein

Since Specialization

Citations

This map shows the geographic impact of Brent A. Blumenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brent A. Blumenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brent A. Blumenstein more than expected).

Fields of papers citing papers by Brent A. Blumenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brent A. Blumenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brent A. Blumenstein. The network helps show where Brent A. Blumenstein may publish in the future.

Co-authorship network of co-authors of Brent A. Blumenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Brent A. Blumenstein. A scholar is included among the top collaborators of Brent A. Blumenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brent A. Blumenstein. Brent A. Blumenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials 2025 ·Thorax ·Judith J. Prochaska, (unknown), Renee Perdok, Brent A. Blumenstein, Cindy Jacobs	0
2	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer 2017 ·Annals of Oncology ·Joaquim Bellmunt, Bernhard J. Eigl, Elżbieta Senkus, Yohann Loriot, P. Twardowski, Daniel Castellano, Normand Blais, Srikala S. Sridhar, Cora N. Sternberg, Margitta Retz, Sumanta K. Pal, Brent A. Blumenstein, Cindy Jacobs, Patricia Stewart, Daniel P. Petrylak	19
3	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial 2017 ·The Lancet Oncology ·Tomasz M. Beer, Sébastien J. Hotte, Fred Saad, B. Yа. Alekseev, В. Б. Матвеев, Aude Fléchon, Gwénaëlle Gravis, Florence Joly, Kim N., Zafar Malik, Brent A. Blumenstein, Patricia Stewart, Cindy Jacobs, Karim Fizazi	67
4	Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer breakdown → 2013 ·Gut ·Timothy R. Church, Michael Wandell, Catherine Lofton–Day, Steven J. Mongin, Matthias Burger, Shannon R. Payne, Esmeralda Castaños‐Vélez, Brent A. Blumenstein, Thomas Rösch, Neal Osborn, Dale C. Snover, Robert Day, David F. Ransohoff	575
5	Using a Powered Bone Marrow Biopsy System Results in Shorter Procedures, Causes Less Residual Pain to Adult Patients, and Yields Larger Specimens 2011 ·Diagnostic Pathology ·James R. Berenson, Ori Yellin, Brent A. Blumenstein, (unknown), (unknown), David M. Aboulafia, (unknown), (unknown)	46
6	Trends in clinical trials in surgical oncology: Implications for outcomes research 2003 ·Clinical Therapeutics ·Ulrich Güller, Brent A. Blumenstein	2
7	Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer breakdown → 2001 ·New England Journal of Medicine ·Robert C. Flanigan, Sydney E. Salmon, Brent A. Blumenstein, Scott I. Bearman, Vivek Roy, Patrick C. McGrath, J. R. Caton, Nikhil C. Munshi, E. David Crawford	1223
8	The Prognostic Significance of S–Phase Analysis in Stage Ta/T1 Bladder Cancer 2000 ·European Urology ·Ralph W. deVere White, Arline D. Deitch, Siamak Daneshmand, Brent A. Blumenstein, Bruce A. Lowe, Arthur I. Sagalowsky, Joseph A. Smith, Paul F. Schellhammer, Thomas H. Stanisic, H. Barton Grossman, Edward M. Messing, John D. Crissman, E. David Crawford	13
9	Cancer pain and common pain: a comparison of patient-reported intensities. 1999 ·PubMed ·Donna L. Berry, Diana J. Wilkie, (unknown), Brent A. Blumenstein	12
10	Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer breakdown → 1998 ·New England Journal of Medicine ·Mario A. Eisenberger, Brent A. Blumenstein, E. David Crawford, Gary J. Miller, David G. McLeod, Patrick J. Loehrer, George Wilding, (unknown), Daniel J. Culkin, Ian M. Thompson, Anton J. Bueschen, Bruce A. Lowe	685
11	Improved detection of recurrent bladder cancer using the bard bta stat test 1997 ·Urology ·Michael F. Sarosdy, M’Liss A. Hudson, William J. Ellis, Mark S. Soloway, Ralph Devere White, Joel Sheinfeld, Mark V. Jarowenko, Paul F. Schellhammer, Edward Schervish, Jaymit Patel, Gerald W. Chodak, Donald L. Lamm, Robert D. Johnson, (unknown), George W. Adams, Brent A. Blumenstein, (unknown), (unknown), H. A. Murchison, Sharon L Brunelle	165
12	Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumors 1997 ·Urology ·William J. Ellis, Brent A. Blumenstein, Laura Ishak, David L. Enfield	116
13	Phase II evaluation of doxorubicin/vinblastine combined with inhibitors trifluoperazine/verapamil of P-glycoprotein in patients with advanced renal carcinoma 1997 ·Urologic Oncology Seminars and Original Investigations ·Louis E. Schroder, Brent A. Blumenstein, (unknown), J R Borst, E. David Crawford	1
14	Phase II Trial of CHIP for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate 1995 ·American Journal of Clinical Oncology ·M. Ernest Marshall, Michael Wolf, E. David Crawford, Geoffrey R. Weiss, Frederick R. Ahmann, Fredrick J. Meyers, Brent A. Blumenstein, Mario A. Eisenberger, Albert Einstein	4
15	MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS 1995 ·The Lancet ·Otilia Dalesio, (unknown), L. Denis, Fritz H. Schröder, Brent A. Blumenstein, Jon Godwin, R Peto	195
16	Serum basic fibroblast growth factor in men with and without prostate carcinoma 1995 ·Cancer ·GRANT E. MEYER, (unknown), (unknown), Jason C. Petteway, Brent A. Blumenstein, Michael K. Brawer	62
17	Phase II trial of menogaril in metastatic adenocarcinoma of the prostate 1994 ·Investigational New Drugs ·Sarah A. Taylor, Brent A. Blumenstein, Ronald L. Stephens, E. David Crawford, (unknown), (unknown)	3
18	Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study 1992 ·European Journal of Cancer ·C. Kent Osborne, Geoffrey R. Weiss, Brent A. Blumenstein, E. David Crawford, Ronald M. Bukowski, (unknown)	14
19	A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. 1991 ·Journal of Clinical Oncology ·Agnieszka Woźniak, Michael K. Samson, (unknown), E. David Crawford, (unknown), (unknown), Ronald L. Stephens, (unknown), Bertha A. Bouroncle, Brent A. Blumenstein	31
20	A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder breakdown → 1991 ·New England Journal of Medicine ·Donald L. Lamm, Brent A. Blumenstein, E. David Crawford, James E. Montie, Peter T. Scardino, H. Barton Grossman, Thomas H. Stanisic, Joseph A. Smith, Jeremy A. Sullivan, Michael F. Sarosdy, (unknown), (unknown)	469

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact